Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor VII deficiency and the FVII mutation database.

J H McVey1, E Boswell, A D Mumford

  • 1MRC Clinical Sciences Centre, Imperial College School of Medicine, London, UK. john.mcvey@csc.mrc.ac.uk

Human Mutation
|January 4, 2001
PubMed
Summary

Factor VII (FVII) is crucial for blood clotting initiation. Mutations in the FVII gene can cause bleeding disorders, but current tests may not accurately reflect in vivo clotting ability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laboratory monitoring of P2Y<sub>12</sub> inhibitors: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Expression and characterization of a codon-optimized blood coagulation factor VIII.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Platelets are a safe way to deliver factor VIII. After 13 years of preclinical research it is now time for a clinical trial.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.

Cell death discovery·2016
Same author

Genomics of platelet disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Area of Science:

  • Coagulation science
  • Genetics
  • Molecular biology

Background:

  • Factor VII (FVII) is a vitamin K-dependent serine protease essential for initiating blood coagulation.
  • FVII is synthesized in the liver and circulates in plasma; its gene (F7) is located on chromosome 13.
  • Mutations in the F7 gene can lead to FVII deficiency, with severe cases being life-threatening due to hemorrhage.

Purpose of the Study:

  • To review the structure, function, and genetic basis of Factor VII.
  • To discuss the clinical implications of F7 gene mutations and FVII deficiency.
  • To highlight the limitations of current in vitro assays in assessing FVII's in vivo coagulation potential.

Main Methods:

  • Literature review of FVII structure, genetics, and clinical phenotypes associated with F7 mutations.

Related Experiment Videos

  • Analysis of data from the FVII mutation database.
  • Discussion of FVII activity assays and their correlation with clinical presentation.

    • Main Results:

    • The F7 gene encodes a 406-amino acid protein with distinct functional domains.
    • Over 238 individuals with F7 mutations are documented, ranging from asymptomatic to severe bleeding phenotypes.
    • Severe bleeding is typically observed with FVII activity below 2% of normal, but mild-moderate phenotypes can present with similar in vitro levels.
    • In vitro assays may lack sensitivity for low FVII levels sufficient for in vivo coagulation.

    Conclusions:

    • FVII deficiency results from F7 gene mutations, impacting blood coagulation initiation.
    • Clinical presentation varies widely, and in vitro FVII activity assays may not fully predict bleeding risk.
    • Further research into sensitive assays is needed to accurately assess FVII function in vivo.